Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28670717.
- Also identified by DOI 10.1111/all.13239.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (T<sub>H</sub> 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from T<sub>H</sub> 2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.
Medical subject headings
- Dermatitis, Atopic
- Interleukins
- Pruritus
- Receptors, Interleukin